The management of interim analyses in drug development

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Drug Development

Background:

• Interim analyses are increasingly used in clinical research beyond life-threatening conditions.
• They offer a potential to reduce drug time-to-market by enabling earlier decision-making.
• However, improper design can compromise trial integrity and drug development programs.

Purpose of the Study:

• To define procedures for the design and management of clinical trials incorporating interim analyses.
• To ensure good clinical and statistical practice is maintained throughout the development program.
• To uphold high scientific standards for both individual trials and the overall drug development effort.

Main Methods:

• Consideration of design, conduct, analysis, and dissemination of results for trials with interim analyses.
• Emphasis on the role and effective utilization of data monitoring committees.
• Integration of statistical principles with clinical trial management practices.

Main Results:

• Established procedures for designing and managing clinical trials with interim analyses.
• Guidelines for maintaining scientific rigor and integrity throughout the drug development process.
• Recommendations for the strategic use of data monitoring committees in confirmatory trials.

Conclusions:

• Well-designed interim analyses are crucial for efficient drug development.
• Adherence to defined procedures ensures the scientific validity of trial results.
• Effective management, including data monitoring committees, is key to successful interim analyses.